Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

PV. Raninga, A. Lee, D. Sinha, LF. Dong, KK. Datta, X. Lu, P. Kalita-de Croft, M. Dutt, M. Hill, N. Pouliot, H. Gowda, M. Kalimutho, J. Neuzil, KK. Khanna

. 2020 ; 10 (12) : 5259-5275. [pub] 20200406

Language English Country Australia

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NV17-30138A MZ0 CEP Register

Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required. Methods: We evaluated anti-cancer activity of a potent proteasome inhibitor, marizomib, in vitro using breast cancer lines and in vivo using 4T1.2 murine syngeneic model, MDA-MB-231 xenografts, and patient-derived tumor xenografts. Global proteome profiling, western blots, and RT-qPCR were used to investigate the mechanism of action for marizomib. Effect of marizomib on lung and brain metastasis was evaluated using syngeneic 4T1BR4 murine TNBC model in vivo. Results: We show that marizomib inhibits multiple proteasome catalytic activities and induces a better anti-tumor response in TNBC cell lines and patient-derived xenografts alone and in combination with the standard-of-care chemotherapy. Mechanistically, we show that marizomib is a dual inhibitor of proteasome and oxidative phosphorylation (OXPHOS) in TNBCs. Marizomib reduces lung and brain metastases by reducing the number of circulating tumor cells and the expression of genes involved in the epithelial-to-mesenchymal transition. We demonstrate that marizomib-induced OXPHOS inhibition upregulates glycolysis to meet the energetic demands of TNBC cells and combined inhibition of glycolysis with marizomib leads to a synergistic anti-cancer activity. Conclusions: Our data provide a strong rationale for a clinical evaluation of marizomib in primary and metastatic TNBC patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026729
003      
CZ-PrNML
005      
20211026132650.0
007      
ta
008      
211013s2020 at f 000 0|eng||
009      
AR
024    7_
$a 10.7150/thno.42705 $2 doi
035    __
$a (PubMed)32373211
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Raninga, Prahlad V $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
245    10
$a Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition / $c PV. Raninga, A. Lee, D. Sinha, LF. Dong, KK. Datta, X. Lu, P. Kalita-de Croft, M. Dutt, M. Hill, N. Pouliot, H. Gowda, M. Kalimutho, J. Neuzil, KK. Khanna
520    9_
$a Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required. Methods: We evaluated anti-cancer activity of a potent proteasome inhibitor, marizomib, in vitro using breast cancer lines and in vivo using 4T1.2 murine syngeneic model, MDA-MB-231 xenografts, and patient-derived tumor xenografts. Global proteome profiling, western blots, and RT-qPCR were used to investigate the mechanism of action for marizomib. Effect of marizomib on lung and brain metastasis was evaluated using syngeneic 4T1BR4 murine TNBC model in vivo. Results: We show that marizomib inhibits multiple proteasome catalytic activities and induces a better anti-tumor response in TNBC cell lines and patient-derived xenografts alone and in combination with the standard-of-care chemotherapy. Mechanistically, we show that marizomib is a dual inhibitor of proteasome and oxidative phosphorylation (OXPHOS) in TNBCs. Marizomib reduces lung and brain metastases by reducing the number of circulating tumor cells and the expression of genes involved in the epithelial-to-mesenchymal transition. We demonstrate that marizomib-induced OXPHOS inhibition upregulates glycolysis to meet the energetic demands of TNBC cells and combined inhibition of glycolysis with marizomib leads to a synergistic anti-cancer activity. Conclusions: Our data provide a strong rationale for a clinical evaluation of marizomib in primary and metastatic TNBC patients.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a apoptóza $x účinky léků $x genetika $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $x genetika $7 D049109
650    _2
$a epitelo-mezenchymální tranzice $x účinky léků $x genetika $7 D058750
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a laktony $x terapeutické užití $7 D007783
650    _2
$a myši $7 D051379
650    _2
$a oxidativní fosforylace $x účinky léků $7 D010085
650    _2
$a proteasomový endopeptidasový komplex $x účinky léků $x metabolismus $7 D046988
650    _2
$a inhibitory proteasomu $x terapeutické užití $7 D061988
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a triple-negativní karcinom prsu $x farmakoterapie $x genetika $x metabolismus $7 D064726
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lee, Andy $u Radiation Biology Research Center, Institute for Radiological Research, Chang Gung Memorial Hospital/Chang Gung University, Taoyuan 333, Taiwan
700    1_
$a Sinha, Debottam $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
700    1_
$a Dong, Lan-Feng $u School of Medical Science, Griffith University, Southport, QLD 4222, Australia
700    1_
$a Datta, Keshava K $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
700    1_
$a Lu, Xue $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
700    1_
$a Kalita-de Croft, Priyakshi $u UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, QLD 4029, Australia
700    1_
$a Dutt, Mriga $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
700    1_
$a Hill, Michelle $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
700    1_
$a Pouliot, Normand $u Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg Vic 3084 Australia
700    1_
$a Gowda, Harsha $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
700    1_
$a Kalimutho, Murugan $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
700    1_
$a Neuzil, Jiri $u School of Medical Science, Griffith University, Southport, QLD 4222, Australia $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West, 252 50 Czech Republic
700    1_
$a Khanna, Kum Kum $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
773    0_
$w MED00177173 $t Theranostics $x 1838-7640 $g Roč. 10, č. 12 (2020), s. 5259-5275
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32373211 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132656 $b ABA008
999    __
$a ok $b bmc $g 1715465 $s 1147236
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 12 $d 5259-5275 $e 20200406 $i 1838-7640 $m Theranostics $n Theranostics $x MED00177173
GRA    __
$a NV17-30138A $p MZ0
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...